homepage-banner.jpg
Mereo-Biopharma---logo.png

Unlocking healthcare potential for patients

Leveraging our expertise to address unmet medical needs

our products

Mereo has acquired an initial mid-late stage portfolio of three exceptionally well characterised novel products for the treatment of diseases with considerable unmet medical need from Novartis Pharmaceuticals.

Each of these programmes has a comprehensive dataset for both pre-clinical and proof-of-concept clinical studies.

Phase 2B*

BPS-804

Osteogenesis Imperfecta (OI) *PIVOTAL
Phase 2B

BGS-649

Hypogonadotropic Hypogonadism (HH)
Phase 2

ACUMAPIMOD - BCT-197

Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)

partner with us

Mereo has been formed to take advantage of the global pharmaceutical industry's drive for creative ways to progress their clinical development pipelines.

Interested in a potential collaboration?

Investors

Share Price

View Share Price Chart

Events and conferences

  • 19 May 2017 Mereo BioPharma to present at the American Thoracic Society meeting in Washington, 19-24 May 2017
  • 24 Jan 2017 Mereo BioPharma to present at the Shares Spotlight Evening in London
  • 10 Jan 2017 Mereo BioPharma Group plc to present at the 9th Annual Biotech Showcase, 11:00am PST (San Francisco, USA)
View All Events